← Tonghua Dongbao Pharmaceutical overview

Tonghua Dongbao Pharmaceutical vs Zhejiang Huahai Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Tonghua Dongbao Pharmaceutical Co Ltd (600867.CG)

Q3 2026
▲2▼2

FDA approval and strong H1 profit offset by high shareholder pledges

  • US FDA approval opens overseas market Tonghua Dongbao's co-developed insulin aspart injection won US FDA approval, letting it sell in the world's biggest insulin market. Novo Nordisk's US insulin aspart sales were about $1.1 billion last year, so this is a real long-term growth opening, not just a headline.

    This is the biggest new positive force, opening a large new market for the company's insulin products.

  • First-half profit jumps 37% on insulin analogue sales First-half 2026 revenue rose 11.13% to 1.553 billion yuan and net profit rose 37.32% to 296 million yuan. Strong sales of insulin glargine and aspart drove domestic growth, and second-quarter profit rose 55.5%. This shows the core business is performing well.

    The interim results are the clearest evidence of underlying business strength and directly support the stock's value.

  • Controlling shareholder pledges over 93% of its shares Dongbao Group repeatedly released and re-pledged tens of millions of shares, leaving 93.94% of its holdings pledged. That is a warning sign: if the share price falls sharply, the shareholder could face margin calls or forced selling, which would hurt ordinary investors.

    This is the main risk weighing on the stock and a real counterweight to the good news.

  • Project termination and impairment slightly reduce profit Tonghua Dongbao scrapped its THDBH110 capsule development project and wrote off 16.89 million yuan, cutting first-half profit by that amount. It is a small hit next to the 296 million yuan profit, but it shows some pipeline bets are not paying off.

    This is a modest but real negative that partly offsets the strong earnings and shows pipeline risk.

August 2026
▲2▼2

FDA approval and strong H1 profit offset by high shareholder pledges

  • US FDA approval opens overseas market Tonghua Dongbao's co-developed insulin aspart injection won US FDA approval, letting it sell in the world's biggest insulin market. Novo Nordisk's US insulin aspart sales were about $1.1 billion last year, so this is a real long-term growth opening, not just a headline.

    This is the biggest new positive force, opening a large new market for the company's insulin products.

  • First-half profit jumps 37% on insulin analogue sales First-half 2026 revenue rose 11.13% to 1.553 billion yuan and net profit rose 37.32% to 296 million yuan. Strong sales of insulin glargine and aspart drove domestic growth, and second-quarter profit rose 55.5%. This shows the core business is performing well.

    The interim results are the clearest evidence of underlying business strength and directly support the stock's value.

  • Controlling shareholder pledges over 93% of its shares Dongbao Group repeatedly released and re-pledged tens of millions of shares, leaving 93.94% of its holdings pledged. That is a warning sign: if the share price falls sharply, the shareholder could face margin calls or forced selling, which would hurt ordinary investors.

    This is the main risk weighing on the stock and a real counterweight to the good news.

  • Project termination and impairment slightly reduce profit Tonghua Dongbao scrapped its THDBH110 capsule development project and wrote off 16.89 million yuan, cutting first-half profit by that amount. It is a small hit next to the 296 million yuan profit, but it shows some pipeline bets are not paying off.

    This is a modest but real negative that partly offsets the strong earnings and shows pipeline risk.

Latest
▲2▼2

FDA approval and strong H1 profit offset by high shareholder pledges

  • US FDA approval opens overseas market Tonghua Dongbao's co-developed insulin aspart injection won US FDA approval, letting it sell in the world's biggest insulin market. Novo Nordisk's US insulin aspart sales were about $1.1 billion last year, so this is a real long-term growth opening, not just a headline.

    This is the biggest new positive force, opening a large new market for the company's insulin products.

  • First-half profit jumps 37% on insulin analogue sales First-half 2026 revenue rose 11.13% to 1.553 billion yuan and net profit rose 37.32% to 296 million yuan. Strong sales of insulin glargine and aspart drove domestic growth, and second-quarter profit rose 55.5%. This shows the core business is performing well.

    The interim results are the clearest evidence of underlying business strength and directly support the stock's value.

  • Controlling shareholder pledges over 93% of its shares Dongbao Group repeatedly released and re-pledged tens of millions of shares, leaving 93.94% of its holdings pledged. That is a warning sign: if the share price falls sharply, the shareholder could face margin calls or forced selling, which would hurt ordinary investors.

    This is the main risk weighing on the stock and a real counterweight to the good news.

  • Project termination and impairment slightly reduce profit Tonghua Dongbao scrapped its THDBH110 capsule development project and wrote off 16.89 million yuan, cutting first-half profit by that amount. It is a small hit next to the 296 million yuan profit, but it shows some pipeline bets are not paying off.

    This is a modest but real negative that partly offsets the strong earnings and shows pipeline risk.

Zhejiang Huahai Pharmaceutical Co Ltd (600521.CG)

Q3 2026
▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

  • Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.

    This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.

  • Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.

    A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.

  • Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.

    Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.

  • US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.

    These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

August 2026
▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

  • Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.

    This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.

  • Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.

    A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.

  • Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.

    Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.

  • US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.

    These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

Latest
▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

  • Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.

    This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.

  • Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.

    A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.

  • Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.

    Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.

  • US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.

    These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.